- Home
- PRHI vs MBRX Comparison
PRHI vs MBRX Comparison
Compare PRHI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRHI | MBRX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 12.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PRHI | MBRX |
|---|---|---|
| Price | $0.72 | $4.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 34.5K | ★ 163.3K |
| Earning Date | 11-12-2025 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,664,000.00 | N/A |
| Revenue This Year | $25.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $3.13 |
| 52 Week High | $2.83 | $91.25 |
Technical Indicators
Market Signals| Indicator | PRHI | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 57.05 |
| Support Level | $0.68 | $4.26 |
| Resistance Level | $0.84 | $5.15 |
| Average True Range (ATR) | 0.08 | 0.37 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 65.70 | 51.02 |
Price Performance
Historical ComparisonAbout PRHI Presurance Holdings Inc.
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.